

## Announcement

### **NeuroSearch's license partner Abbott initiates clinical Phase II study with ABT-894 in neuropathic pain**

NeuroSearch's development and license partner Abbott has initiated a clinical Phase II study with the drug candidate, ABT-894, for the treatment of diabetic neuropathic pain (severe chronic pain conditions). The first patient has been enrolled and dosed in the study.

This clinical Phase II study is a randomized, double-blind and placebo-controlled dose-ranging trial to evaluate the efficacy of ABT-894 in patients suffering from diabetic neuropathic pain. For further study details please see:

**<http://www.clinicaltrials.gov/ct/show/NCT00507936?order=1>**.

ABT-894 is a subtype selective modulator of Neuronal Nicotinic Acetylcholine receptors (NNR), which showed promising effects in pre-clinical models for pain and other central and peripheral nervous system diseases. Abbott is also conducting a clinical Phase II study with ABT-894 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The ADHD-study was initiated in March 2007 and is progressing according to plan.

Under the terms of the license agreement, Abbott is responsible for the clinical development and commercialisation of ABT-894 and will finance all development costs. NeuroSearch will receive milestone payments as well as royalties on Abbott's global sales.

The initiation of the Phase II study with ABT-894 in diabetic neuropathic pain does not change NeuroSearch's financial expectations for 2007 of a loss in the range of DKK 230-250 million before recognition of associates and other equity interests as stated in the H1 report 2007 issued on 22 August 2007.

Asger Aamund  
Chairman of the Board

### **Contact persons:**

Flemming Pedersen, CEO, phone: +45 4460 8214 or +45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications, phone: +45 4460 8212 or +45 4017 5103

07.09.2007

Announcement no. 23-07

Page 2 of 2

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 11 clinical development programmes: ACR16 in Huntington's disease (Phase III preparation), tesofensine in obesity/type 2 diabetes (Phase II), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder (Phase I) and ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.